Unlucky versus coincidence: Dual hepato-pancreatico biliary diagnoses in a six-year-old  by Campbell, Beth M. et al.
Contents lists available at ScienceDirect
J Ped Surg Case Reports 14 (2016) 15e18Journal of Pediatric Surgery CASE REPORTS
journal homepage: www.jpscasereports .comUnlucky versus coincidence: Dual hepato-pancreatico biliary
diagnoses in a six-year-old
Beth M. Campbell*, Craig A. McBride, Jonathan W. Fawcett
Lady Cilento Children’s Hospital, Stanley St, South Brisbane, QLD 4101, Australiaa r t i c l e i n f o
Article history:
Received 23 May 2016
Received in revised form
21 August 2016





Choledochal cyst* Corresponding author.
E-mail address: Beth.Campbell2@health.qld.gov.au
2213-5766/Crown Copyright  2016 Published by Elsev
0/).
http://dx.doi.org/10.1016/j.epsc.2016.08.006a b s t r a c t
We describe a case of inﬂammatory myoﬁbroblastic tumor presenting as a head of pancreas mass in a
six-year-old girl. The etiology of such lesions is elusive, with a poorly understood malignant potential.
One hypothesis is that they occur in areas of inﬂammation and trauma. The tumor occurred two years
after this same patient had a Type I choledochal cyst excised with Roux-En-Y hepaticojejunostomy.
Crown Copyright  2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Inﬂammatory myoﬁbroblastic tumors (IMTs) have undergone
many nomenclature changes in recent years, reﬂecting incomplete
understanding of their etiology, pathogenesis and clinical behavior
[1]. Also known as inﬂammatory pseudotumors or plasma cell
granulomas, they are rare neoplasms [1], and rarer still in children.
This report presents a child who developed an IMT in a post-
operative ﬁeld.
1. Case report
A 6-year-old female presented with a one-month history of
fatigue, vomiting, anorexia, early satiety and weight loss. She had
no abdominal pain and physical examination was unremarkable
with neither jaundice nor a palpable abdominal mass being noted.
Ultrasound investigation revealed a right hypochondrial mass. A
portal venous contrast computed tomography (CT) study of the
abdomen showed a 6  6.2 cm mass arising from the head of
pancreas, with atrophy of the pancreatic body and tail. No biliary or
pancreatic ductal dilatation was noted and there were no other
lesions (Fig. 1). Blood tests showed a microcytic anemia with
normal inﬂammatorymarkers, normal hepatic and renal function, a
lipase of 79 U/L (normal value < 60 U/L), and a normal ferritin.(B.M. Campbell).
ier Inc. This is an open access articTwo years previously, a Type I choledochal cyst had been diag-
nosed in this patient after she presented with obstructive jaundice.
She underwent an uncomplicated choledochocystectomy with
Roux-En-Y hepaticojejunostomy. Pathological examination of the
resected specimen demonstrated a choledochal cyst with chronic
inﬂammation and ﬁbrosis. She made a full recovery, and 6 monthly
post-operative ultrasound scans were normal prior to her symp-
tomatic presentation.
An endoscopic retrograde cholangiopancreatogram (ERCP) was
organized to obtain a tissue diagnosis. Examination of the biopsy
specimens taken showed a stromal lesion of intermediate biological
behavior, favoring an IMT. The biopsies were positive for anaplastic
lymphoma kinase (ALK), B-cell lymphoma 2 (BCL2) and Cyclin D1;
human herpesvirus 8 (HHV8) was negative.
Following multidisciplinary consultation, crizotinib (Pﬁzer,
New York City, USA), an ALK and ROS1 inhibitor, was prescribed
prior to planned resection. Shrinkage of the tumor to
2.8  2.4 cm over 4 months was observed. The patient went on
to have a pancreaticoduodenectomy (Fig. 2) with posterior
pancreaticogastrostomy and anterior gastrojejunostomy (Fig. 3).
The previous hepaticojejunostomy was left undisturbed. Histo-
logical margins were tumor free. She made a speedy recovery
but was readmitted a short time later with delayed gastric
emptying which resolved with parental nutrition support and
gut rest. She remains well nine months later, with no evidence of
recurrence.le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
Fig. 1. Coronal and axial computed tomography images demonstrating the head of pancreas mass measuring approximately 6  6 cm.
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IMTs are rare, solid lesions occurring most commonly in the
bronchial tree, retroperitoneum and abdominal cavity [2]. When
examined histologically, they are composed of ﬁbroblast and
myoﬁbroblast inﬁltrates with a background chronic inﬂammatory
inﬁltrate of eosinophils, plasma cells and lymphocytes. Although
they clinically and radiologically mimic neoplasms, IMTs have
questionable potential for aggressive behavior. Recognition of ALK
gene rearrangement and cytogenetic aberrations support the
concept of IMTs being a neoplastic lesion and as such the World
Health Organisation classiﬁes them as a distinctive neoplasm with
intermediate biological behavior [2]. Complete surgical excision
appears to be curative although cases of metastatic disease have
been reported [3]. Evidence suggests that pathological features of
atypia, p53 expression and aneuploidy may predict IMTs with more
aggressive potential [4].
Several biological markers have been identiﬁed as having diag-
nostic and therapeutic importance, although these are not speciﬁc
for IMTs. Anaplastic lymphoma kinase (ALK) rearrangements on
chromosome 2p23 result in aberrant ALK expression in 40e50% of
IMTs [5,6]. Children and young adults diagnosed with IMTs appear
more likely than adults over the age of 40 to harbor ALK rear-
rangements in the myoﬁbroblastic component of the tumor; the
inﬂammatory component does not exhibit this change. ALK
inhibitors such as crizotinib are therefore potentially of beneﬁt.Fig. 2. Pancreaticoduodenectomy specimen. Arrow points to area of IMT which had a
rubbery consistency.Given the location of our patient’s disease and the desire to
perform a less extensive, albeit complete, resection, neo-adjuvant
treatment was used with the intention of shrinking the lesion. IMT
response to crizotinib has been described. Butrynski et al. [6]
reported a partial response to crizotinib in a 44-year-old man
with diffuse intraabdominal IMT harboring ALK rearrangement
detected by ﬂuorescent in situ hybridisation (FISH). Following
surgical debulking, the initial substantial response to therapy lasted
6 months, after which the tumor began to re-grow. After further
surgical debulking of the recurrent tumor, the patient remains on
long-term crizotinib with no radiological evidence of recurrence.
The second patient in Butrynski’s report was a 21-year-old male
with a gastric IMT. The resected specimen was negative for ALT
rearrangement and when recurrent disease was detected ﬁve
months later, crizotinib was initiated and re-staging showed
worsening of disease with no response to therapy. The authors
concluded that there was potential for long-term response in
favorable tumor cell populations to crizotinib; this formed the
rationale for administration of the drug to the patient described in
our paper. Her response gives further support to Butrynski’s ﬁnd-
ings. Further, targeted ALK therapy in pediatric malignancies was
found to be safe in a Phase 1 trial in patients aged 12 months to 22
years [7]. Anti-tumor activity was enriched in patients with known
ALK rearrangements and the drug was well tolerated. Phase 2 of
this US trial is due for completion in 2017 [8].
The etiology of IMTs has remained elusive since they were ﬁrst
described in 1939 [9]. Neoplastic, infectious, autoimmune and
genetic etiologies have all been proposed. Identiﬁcation of human
herpesvirus 8 (HHV-8) and EpsteineBarr virus (EBV) DNA
sequences in IMT specimens was initially promising [10,11]
although this has not been substantiated in pediatric case series
[3,12]. Human interleukin 6 (IL-6) and cyclin D1 overexpression
have been reported in a case series of 7 patients [13], and p53
modulated alterations have been implicated in those IMTs
harboring malignant transformation [2].
Accurate demographic data regarding anatomical sites affected
by IMTs are difﬁcult to obtain given the interchangeable terms
historically used to describe these lesions. Janik et al. [14] collated
274 pediatric cases of IMTs reported in the literature: this is perhaps
the largest summative series. One third of IMTs occurred in the
pulmonary tree. Intra-abdominal IMTs made up the majority of
extrapulmonary locations with the omentum, retroperitoneum and
mesentery being the most common. IMTs have a predilection for
patients in the ﬁrst two decades of life, with the youngest published
Fig. 3. Representation of a) choledochocystectomy with Roux-En-Y hepatico-jejunostomy. The hepaticojejunostomy was performed in a retrocolic fashionwith a 40 cm jejunal limb;
and b) pancreatico-duodenectomy with posterior pancreatico-gastrostomy and anterior jeju-jejunostomy. HJ: Hepatico-jejunostomy; JJ: jeju-jejunostomy; GJ: gastro-jejunostomy
(anterior stomach); PG: pancreatico-gastrostomy (posterior stomach).
B.M. Campbell et al. / J Ped Surg Case Reports 14 (2016) 15e18 17intra-abdominal case being in a 7-day-old infant [15]. Only 28 cases
of pediatric pancreatic IMT have been described, with 60% located
in the pancreatic head [16].
Controversies abound in discussions about IMTs, particularly
regarding their etiology. Some authors consider them a reactive
proliferation, while to others they represent a true neoplasm. Brunn
believed IMTs to be benign proliferative reactions occurring in the
lung in his 1939 paper [9]. It was not until the 1990s that the
aggressive potential of IMTs was recognized when Meis and
Enzinger [17] published a case series of 38 children and adolescents
with follow-up data showing signiﬁcant rates of local and wide-
spread recurrence; 5 patients died from their disease. At this time
the term ‘inﬂammatory ﬁbrosarcoma’ was used to label the lesions,
reﬂecting the spindle cell proliferation and prominent inﬂamma-
tory inﬁltrate. Advancement of genomic and molecular knowledge
over time has enabled researchers to identify speciﬁc clonal
rearrangements such as those involving chromosome 2q, further
supporting the neoplastic nature of these lesions.
A unifying cause has yet to be positively identiﬁed. There is an
antecedent history of tissue trauma in a percentage of patients with
IMTs; this may be surgical, immunological, infective or inﬂamma-
tory [18]. This lends some support to the hypothesis IMTs are an
aberrant response to tissue injury. HHV-8 and EBV were initially
explored as candidate etiologies with little success. The ﬁnding of
IL-6 mRNA and protein production in tumor cells is thought to
cause some of the systemic symptoms patients with IMT experi-
ence; these symptoms resolve on surgical resection of the lesion.
Similar ﬁndings are seen with the lymph node hyperplastic disor-
der Castleman disease, prompting some authors to propose there
may similar underlying mechanisms at play [10,19,20].
The question of whether IMTs arise in, or adjacent to, post-
operative sites is intriguing. Several case reports document IMTs
occurring months to years after the resection of neoplasms. Nine
years after the successful treatment of a right-sided Wilms tumor,
Vujanic et al. [21] report a child who had an intra-abdominal IMT
diagnosed. He presented with progressive dysphagia and abdom-
inal swelling and was diagnosed with an IMT involving the gastro-
eosophageal junction, stomach and liver. The Wilms tumor had
been treated with 4 weeks of preoperative chemotherapy followed
by a right radical nephrectomy. Four further patients were reported
with IMTs following the successful treatment of childhoodmalignancies. Two patients had Wilms tumors, one a left hemi-
thoracic Askin tumor, and one nodular sclerosing Hodgkin disease.
All IMTs subsequently occurred in the post radiotherapy or surgical
ﬁeld, up to 10 years later. Although by no means conclusive, the
authors present these cases as anecdotal evidence of increasing
incidence of IMTs after treatment of malignancy. This scenario also
presents a diagnostic dilemma in differentiating these lesions from
primary relapse [22]. A 12-year-old boy had an IMT resected from a
post-auricular site that had had an antecedent trauma ﬁfteen days
prior. The area had been pierced with a sharp pen, resulting in
ulceration with purulent discharge from the site. This was followed
by a progressively enlarging mass, prompting resection. Histologi-
cal examination of this mass revealed an IMT [23]. All such reports
are compelling if one considers IMTs to occur in previous sites of
surgical or accidental trauma. This could certainly explain the
inﬂammatory component of the lesions. The case we describe
supports this link.
All prior abdominal imaging on our patient was retrospectively
re-examined. Despite knowledge of her subsequent course, no
lesion was found on review of her radiology. Ultrasound has
50e70% sensitivity for detection of pancreatic lesions in adults; this
ﬁgure is greater in children given the ability of the sonographic
waves to penetrate a greater distance given the smaller size of the
child and the relatively fat-free intra-abdominal content [24]. CT
with intravenous contrast is somewhat more sensitive, detecting
76e92% of pancreatic lesions [25,26]. It is possible that the lesion
was missed but prior views of the region were clear, in particular
her scan 5 months before her acute presentation.
The debate regarding the etiology of IMTs continues: Are they
truly neoplastic or a reactive pseudotumorous proliferation? The
case described here gives further evidence favoring a reactive
proliferation in a post-surgical ﬁeld, albeit an aberrant one with, for
example, clonal expansion being present. IMTs are rarely diag-
nosed: rarer still to have two uncommon diagnoses in the one
patient. An as yet undiscovered viral, pathological or inﬂammatory
agent has not been precluded as the initiating event. The rarity of
IMT and confusion arising from varied historical descriptions of
tumors that are recognizably IMT contribute to ongoing difﬁculties
in deﬁning these lesions. Accumulating further case reports, such as
this one, will perhaps lead to future insights into causative
mechanisms.
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